The ASX All Ords dividend stock has come under heavy selling pressure in 2025. It’s now trading on a fully franked 8% ...

The firm’s unlisted high-conviction equities strategy is more than 44 per cent invested in healthcare stocks. The biotech has ...

Opthea (NASDAQ:OPT – Get Free Report) was downgraded by research analysts at Leerink Partners from an “outperform” rating to a “market perform” rating in a research note issued on Tuesday, Marketbeat.

Australian money managers Regal Partners Ltd. and Pengana Capital Group Ltd. are facing increased scrutiny from investors ...

HC Wainwright downgraded shares of Opthea (NASDAQ:OPT – Free Report) from a buy rating to a neutral rating in a research report released on Tuesday morning, MarketBeat.com reports. The firm currently ...

Following Regal's lead, Hearts & Minds Investments has now also revalued its holding in Opthea following its failed clinical trials.

Fintel reports that on March 25, 2025, Jefferies downgraded their outlook for Opthea Limited - Depositary Receipt () ...

Leerink downgraded Opthea (OPT) to Market Perform from Outperform with a price target of $1, down from $12. The firm cites the company ...

Trading in shares of Opthea remains halted in the U.S. and Australia after the clinical-stage biopharmaceutical company said its lead product candidate, sozinibercept, failed in a late-stage study in ...

Opthea Ltd. is considering its options after lead candidate sozinibercept (OPT-302) failed the phase III Coast trial in wet age-related macular degeneration (AMD). The global Coast phase III trial ...

Investors have wiped more than $100m from the value of Regal Funds, amid fears that a position in one of its stocks – last ...